A single bad Paragraph IV can cost a generic drugmaker $50 millionheres how.
If you think Paragraph IV litigation is just a legal exercise, this story should change your mind.
On its face, a Paragraph IV notice letter is supposed to be clean, precise, …
The Agitation:
Theres a specific kind of quiet desperation in pharma right before the at-risk launch decision. Not because the product isnt goodor because the science isnt therebut because the calendar is. Patents dont care about your manufacturing tim…
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Evergreening is realbut the 20-patent thicket story is often too neat.
Regulators, investors, and pharma leaders all talk about evergreening as if its a single play: patent stacking to delay competition. But the truth is less cinematicand more operat…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Most patent cases arent won in court. Theyre won in the gap between filing and enforcement.
Thats the hidden ROI in challenging a weak method-of-use patent earlybefore it becomes a habitual pay-to-delay lever in the background of the drug launch calend…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In generic drug litigation, everyone loves a headline: First-to-file gets 180 days of exclusivity.
It sounds like a guaranteed payday. File first, stand in the golden lane, an…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
ð¨ Drug patent settlements shouldnt be treated like a business as usual.
Theyre not a clean exit. Theyre a complex betoften made with imperfect information, under time pressure, and in the face of real legal and statistical uncertainty. And yet, in…
Device patents rarely get the headlinesuntil they do. The quickest way a fortress patent falls is often not through the biggest, most obvious breach, but through the weakest wall. And in pharma patent disputes, that wall is frequently the device side o…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The Salt Change Trap: When a New Patent Buys You Nothing
In pharmaceuticals, patents arent just legal instrumentstheyre commercial levers. And nowhere is that more visible than the increasingly common salt change strategy: a seemingly minor tweak to a …
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
The Six-Month Fuse Is Running OutAnd Pediatric Exclusivity May Be the Liability, Not the Shield
Theres a quiet assumption in biotech and pharma that certain policy levers always help innovators. One of the most common: pediatric exclusivity, often fram…
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
𧩠The real battleground in pharma isnt just who invented itits who can keep it protected.
In a recent decision highlighted by DrugPatentWatch, Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd. spotlights a familiar, but still high-s…
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Get new actionable insights and updates from BiotechBlog
